



Cardinal Health and Gala Design Enter into Strategic Relationship for Manufacturing Biopharmaceuticals

DUBLIN, Ohio and MIDDLETON, Wis., October 14, 2002 -- Cardinal Health, Inc. (NYSE: CAH), the leading provider of products and services supporting the health care industry, and Gala Design, Inc. today announced a strategic relationship to fully leverage Gala's proprietary gene insertion technology for the manufacture of biopharmaceuticals. This agreement extends the broad and innovative drug development services offered by Cardinal Health.

The complementary capabilities of Cardinal Health and Gala will provide biopharmaceutical customers with a direct bridge between biotechnology and therapeutic product delivery, addressing the needs of the rapidly growing therapeutic protein market. The relationship creates an integrated pipeline spanning protein drug discovery to commercial manufacture as well as lyophilization, fill and packaging of sterile parenteral products. Gala's patent pending Gene Product Expression (GPEX™) gene insertion technology allows rapid creation of stable mammalian cell lines with high gene copy numbers, enhancing protein yields to permit efficient pilot plant and large-scale production of monoclonal antibodies and other therapeutic proteins. Through insertion of multiple copies of the gene or genes of interest into mammalian cells, Gala can create stable cell lines that exhibit significantly higher levels of expression than cell lines created using traditional methods and in as little as half the time.

Gala will work directly with the Pharmaceutical Technologies and Services (PTS) segment of Cardinal Health which provides broad development, compliance and manufacturing technologies and services that enable biopharmaceutical customers to make a seamless transition of their protein drug development candidates to a commercial scale. PTS capabilities include a biomanufacturing facility in Raleigh, N.C. as well as product development, and genomic and proteomic analytical services provided by the recently acquired Magellan Laboratories.

Under the agreement, Cardinal Health has invested \$7 million in Gala, with an option to invest another \$3 million. The investments will be used to expand Gala's operations and accelerate its business development efforts. Over the next 12 months, Gala expects to significantly increase its current 32-person team. Gala's recently occupied Middleton, Wisconsin facilities include Phase II scale capability for cGMP biomanufacturing.

"This new relationship with Gala again demonstrates Cardinal Health's commitment to providing full value to the rapidly expanding and evolving biopharmaceutical industry," said Frank Leo, President of the Sterile Technologies Group within the Pharmaceutical Technologies and Services segment of Cardinal Health. "Through this relationship we can offer another proprietary platform technology, and link our customers to the range of

Cardinal Health offerings including manufacturing, packaging and other commercialization services.”

“Our relationship with Cardinal Health will allow us to address key challenges facing the biopharmaceutical industry – delivering the innovative therapeutic products of biotechnology to the patient,” said Paul Weiss, Ph.D., President of Gala. “Our GPEX™ technology has the potential to become the industry standard for creating stable high-expressing mammalian cell lines, addressing the critical need for superior speed and yield in biomanufacturing, and enabling the efficient production of biopharmaceuticals.”

“Our joint technology and services platforms offer an ideal fit to speed up protein evaluation and development, as well as addressing large scale production requirements,” added Bob Bremel, Ph.D., Chief Scientific Officer of Gala. “With the recent publication of the human genome, we are well positioned to offer a high throughput gene expression system and to be a part of the next wave of biopharmaceutical protein discovery, development and commercialization – essentially, the genome-to-patient pipeline.”

ABOUT CARDINAL HEALTH

Cardinal Health, Inc. (www.cardinal.com) is the leading provider of products and services supporting the health care industry. Cardinal Health companies develop, manufacture, package and market products for patient care; develop drug-delivery technologies; distribute pharmaceuticals, medical-surgical and laboratory supplies; and offer consulting and other services that improve quality and efficiency in health care. Headquartered in Dublin, Ohio, Cardinal Health employs more than 49,000 people on five continents and produces annual revenues of more than \$44 billion. Cardinal Health is ranked #23 on the current Fortune 500 list and was named one of the “The World’s Best” companies by Forbes magazine in 2002.

ABOUT GALA

Gala Design, Inc. (www.gala.com) is a privately held biotechnology company located in Middleton, Wis. that has developed enabling technology for the production of pharmaceutical proteins. The company’s technology addresses two acute needs of the pharmaceutical industry: the need to evaluate the properties of proteins coded for by newly identified genomic elements; and the requirement of cost effective large-scale manufacturing of successful drug proteins. Gala’s GPEX™ system focuses on early stage expression and manufacturing in mammalian cell bioreactors, while its Transgametic® gene insertion system is used to produce proteins in cow’s milk.

###